About AVT
Browse Articles
Customer Services

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Please note that the journal is running later than expected due to COVID-19.

During the transition, you can still access content to which you have subscribed via the AVT website. Content will be available to access via the SAGE Journals platform in Summer 2021. https://uk.sagepub.com/en-gb/eur/antiviraltherapy.

If you have any questions relating to the transfer, please contact journaltransitions@sagepub.com

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Subscriptions Please note that Antiviral Therapy is running later than expected due to COVID-19.

All subscription queries should be sent to subscriptions@sagepub.co.uk

Orders via subscription agents
If you are using a subscription agent, please instruct your agent as usual. We are notifying all subscription agents of this change of publisher and they will be able to handle your query.

Pricing enquiries 2021 Antiviral Therapy pricing set by International Medical Press will be honoured.

From the first issue of Volume 26 (2021) Antiviral Therapy will be published by SAGE Publishing.

Please continue to submit your manuscripts to the AVT ScholarOne site (https://mc.manuscriptcentral.com/avt)

For papers already in peer-review, you will be informed of a decision as soon as possible. All accepted papers not assigned to a 2020 issue will now be published by SAGE.

Editorial Policy

Manuscripts submitted to Antiviral Therapy are considered for publication on the understanding that the work contained therein has not been submitted simultaneously to another journal. Copies of related manuscripts submitted elsewhere or in press should accompany the submitted manuscript.

All submissions must be accompanied by a covering letter (a template is available to download), signed by all authors (or by the corresponding author on behalf of all others) stating that all authors have contributed to the paper and are familiar with the contents of the final draft, and that all authors meet the criteria for authorship as established by the International Committee of Medical Journal Editors. The letter should also state whether an author has any conflict of interest.

Sources of funding, any influence the funding source might have had on the analysis and reporting of the results and any related interest must be declared in the Acknowledgements section of your manuscript. All disclosures and declarations must also be summarized in the manuscript. Illustrations and material obtained from other sources must be acknowledged, and documentation showing permission for reproduction from the original publisher must be provided to the Editorial Office upon request.


All manuscripts should be submitted via the ScholarOne Manuscripts™ online submission site. Manuscripts should not be submitted via e-mail or post.

Papers will be peer-reviewed and assessed statistically before acceptance. Priority and time of publication of accepted material will be decided by the Editors. The Editors retain the right to shorten material accepted for publication. This can include subediting the text for style. The Editors endorse the guidelines on good publication practice from the Committee on Publication Ethics (COPE) and GPP3.


Papers based on clinical investigation must conform to ethical standards as set out in the Declaration of Helsinki. Reports describing data obtained from experiments performed in animals must clearly indicate that humane standards were adhered to.

For experiments on isolated tissues the paper must indicate precisely how the donor tissue was obtained. The NIH Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publications) gives guidelines for the acquisition and care of animals.

Reporting guidelines

Randomized controlled trials
Authors are requested to report RCTs in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement. For behavioural and public health evaluations involving non-randomized designs, authors should include with their submission a complete checklist from the TREND statement.

Observational studies
Observational studies include cohort, case-control or cross-sectional designs. These should be reported according to the STROBE recommendations.

Systematic reviews and meta-analyses
Authors are requested to report systematic reviews in accordance with the PRISMA statement and the Cochrane Collaboration guidelines. All literature reviews must contain a brief section entitled 'Search strategy and selection criteria'. This should state clearly the sources (databases, journals, or book reference lists, etc.) of the material covered and the criteria used to include or exclude studies (for example, English language only or studies conducted after a specific date).

Immediate publication and indexing

From July 2012, accepted non-commissioned articles will be published online immediately given the following criteria are met:

• any relevant fees (e.g., colour print) have been paid to the Editorial Office
• copyright forms have been completed and returned to the Editorial Office
• documentation is provided showing permission to use any reproduced or adapted display items
• the article title, author list and abstract are finalized and approved by the corresponding author

Immediately published articles will appear within PubMed and can be cited via a digital object identifier (doi).

A fully edited version of the article will be prepared and published online and in print with the full issue it has been assigned to.


Antiviral Therapy has an open archive initiative wherein research articles are freely accessible after 12 months of their print publication date. We also extend open access to all articles to developing nations via HINARI, which provides free online access to institutions within countries whose resources would otherwise prevent them from subscribing and accessing journal content.

Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.